Pharma Foods International Co., Ltd. (2929) Stock Price

Pharmafoods is a company engaged in research and development and manufacturing of functional ingredients, as well as planning and sales of supplements, quasi-drugs, and cosmetics, and drug discovery research. The company focuses on creating drug candidates using its proprietary functional ingredients and antibodies and peptides, and also provides research support services.

The company's primary customers include food and pharmaceutical manufacturers, distributors, drugstores, general consumers purchasing through mail order, and research institutions and pharmaceutical companies. Revenue is generated through multiple streams: sales of materials to corporate clients, contract manufacturing, direct sales via mail order, research outsourcing fees, and drug discovery licensing income.

Operations are divided into four segments: business-to-business (B2B), business-to-consumer (B2C), biomedical, and other investment and related businesses. The B2B segment sells functional ingredients such as Pharma GABA, Bone Peptide, and HGP, handles contract manufacturing, and supplies drugstores. The B2C segment markets products including Neumo hair growth treatment, Lactron tablets, Sybora Night 2, and WMOA eyelash serum through mail order. The biomedical segment provides antibody drug discovery using the ALAgene platform, peptide development for rare diseases, and research support services including protein analysis. Subsidiaries and affiliated companies engage in diverse businesses including investment operations and solar power and food service ventures.

The company aims to become "a leading healthcare company" and has set a medium to long-term revenue target of 100 billion yen. To achieve this, it is launching a growth investment program of approximately 300 billion yen, funded through operating cash flow from B2B and B2C businesses, capital raising, and monetization of held assets. As part of this growth investment, the company is allocating approximately 10 billion yen to M&A focused on discontinuous growth, with plans to increase operating cash flow through investment returns and expand shareholder returns.

Priority investment areas are research, development, and manufacturing of functional materials. Specifically, the company is investing over 50 billion yen combined in developing "Pharma GABA" for GRAS certification in the United States and biomanufacturing projects centered on eggshell membrane, while also investing approximately 125 billion yen in constructing a new pharmaceutical manufacturing facility. The company differentiates itself by developing materials based on proprietary research and combining contract manufacturing with in-house branded finished products, while strengthening value creation through upcycling of unused resources.

For new market development, the company is pursuing dual strategies: expanding distribution through domestic drugstores and convenience stores, and direct sales via mail order and its own e-commerce platform. Internationally, the company plans to strengthen expansion into Southeast Asia centered on North America and China, while recruiting and developing sales personnel with expertise in distribution, supply chain management, and overseas markets to drive sales growth. Beyond expanding existing businesses, the company actively pursues M&A and alliances to enter new fields such as agriculture and chemical products.

In technological innovation, the company is focusing on strengthening its drug discovery platform and leveraging digital technology. Through improvements to ALAgene technology and adoption of AI and bioinformatics, the company aims to create next-generation antibodies in therapeutic areas with limited treatment options, while expanding its drug discovery pipeline and accelerating development through collaborative research. Additionally, the company is improving efficiency and security in call centers, e-commerce, order and advertising management systems, while establishing an integrated system spanning customer service, research and development, manufacturing, and sales.